{"schema_version":"secwatch.filing_event.v1","accession":"0000934549-24-000003","form_type":"8-K","ticker":"ACTG","cik":"0000934549","company_name":"ACACIA RESEARCH CORP","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.350453+00:00","generated_at":"2026-06-06T20:56:56.034445+00:00","sec_items":["2.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acacia Research sells entire Arix stake for $57.1M to RTW Biotech","bullets":["Sold 33,023,210 Arix shares for $57,078,670 aggregate (~£1.43/share).","Buyer: RTW Biotech Opportunities Operating Ltd, a subsidiary of RTW Biotech Opportunities Ltd.","Transaction closed January 19, 2024; Acacia no longer owns any Arix shares."],"urls":{"canonical":"https://secwatch.observer/filing/0000934549-24-000003","json":"https://secwatch.observer/filing/0000934549-24-000003.json","markdown":"https://secwatch.observer/filing/0000934549-24-000003.md","text":"https://secwatch.observer/filing/0000934549-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/934549/000093454924000003/0000934549-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/934549/000093454924000003/actg-20240119.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:56:56.034445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"685035e35ceef66150eb97d50bac528c01ab9ac4","claim":"ACACIA RESEARCH CORP completed a disposition involving RTW Biotech Opportunities Operating Ltd for US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP) (closed 2024-01-19).","evidence_excerpt":"On January 19, 2024, Acacia Research Corporation (the “Company”) completed the sale of its 33,023,210 shares of Arix Bioscience PLC (“Arix”) to RTW Biotech Opportunities Operating Ltd, a subsidiary of RTW Biotech Opportunities Limited, for US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/934549/000093454924000003/0000934549-24-000003-index.htm","confidence":0.99,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"RTW Biotech Opportunities Operating Ltd"},{"label":"Consideration","value":"US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP)"},{"label":"Closing","value":"2024-01-19"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}